Marplan (isocarboxazid)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Nonselective monoamine oxidase inhibitors block oxidative deamination of naturally occurring monoamines and are used as antidepressants.
USES: This medication is used to treat depression. Isocarboxazid belongs to a class of drugs known as monoamine oxidase inhibitors (MAO inhibitors). It works by helping to restore the balance of certain natural substances in the brain.
Generic name: isocarboxazid
Pronunciation: (EYE-soe-kar-BOX-a-zid)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Marplan
Indications
The following indications are listed for Marplan:
- Major Depressive Disorder
Also known as: Major Unipolar Illness, Unipolar Mood Disorder.
Dosing
There is a wide range of individual requirements for MAO inhibitor dosage, and dosage must be carefully adjusted according to individual requirements and response, using the lowest possible effective dosage. The initial dosage may be increased gradually according to the patient's tolerance and therapeutic response; however, because therapeutic response to the drugs may be delayed for several days to up to 4 weeks or more, sufficient time should be allowed between increases in dosage. Some manufacturers recommend that at least 1-2 weeks elapse between dosage adjustments. Dosage should be increased more gradually in debilitated, emaciated, or geriatric patients.
Patients receiving MAO inhibitors should be monitored for possible worsening of depression, suicidality, or unusual changes in behavior, especially at the beginning of therapy or during periods of dosage adjustment. (See Worsening of Depression and Suicidality Risk under Cautions: Precautions and Contraindications.)
Monoamine oxidase (MAO) inhibitors are administered orally.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Safety of MAO inhibitors during pregnancy has not been established. Administration of phenelzine to pregnant mice resulted in a decrease in the number of viable offspring, and the growth of young dogs and rats has been retarded by phenelzine dosages exceeding the maximum human dosage. Tranylcypromine has been shown to cross the placenta in rats. It is not known whether MAO inhibitors can cause fetal harm when administered to pregnant women, and the drugs should be used during pregnancy only when the potential benefits justify the possible risks to the fetus.
It is not known if MAO inhibitors are distributed into human milk; however, tranylcypromine is distributed into the milk of lactating dogs. MAO inhibitors should be used with caution in nursing women.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.